(Q77309728)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

title

Valsartan in heart failure patients previously untreated with an ACE inhibitor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

author name string

V P Mazayev

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

I G Fomina

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

E N Kazakov

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

V A Sulimov

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

T V Zvereva

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

V A Lyusov

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

V A Orlov

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

L I Olbinskaya

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

T D Bolshakova

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

J Sullivan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

D O Spormann

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

language of work or name

English

0 references

publication date

1 August 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Cardiology

4 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

239-246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

4 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Systemic, pulmonary, brachial, renal and hepato-splanchnic hemodynamic effects of spirapril in severe congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

ACE inhibitors in heart failure: prospects and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Treatment of congestive heart failure: experience with fosinopril

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Effect of enalapril on mortality in congestive heart failure. Follow-up survival data from the CONSENSUS trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2898%2900149-1

7 January 2021

10.1016/S0167-5273(98)00149-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9740480%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference